One potential target is the peroxisome proliferator-activated receptor gamma (PPAR-γ) protein, which is considered the master regulator of adipogenesis, is involved in macrophage inflammatory response, and has been a major target for the pharmacological treatment of type 2 diabetes (T2D) and obesity [39, 40]. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.